CD207 and familial atrioventricular septal defect: Finally, we could demonstrate that the clinically approved drug bortezomib, by reducing the expression of SASP cytokines and inhibiting CD1a+CD207+LCH cell proliferation, is an interesting drug to be repurposed for the treatment of LCH and ECD.